NASDAQ:KROS | Free Cash Flow | Keros Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2019-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$3.53M$73,000.00-$3.6M
2025-12-31-$27.29M$134,000.00-$27.43M
2025-03-31$161.17M$565,000.00$160.61M108.19%
2024-12-31-$46.01M$289,000.00-$46.3M
2024-03-31-$44.56M$946,000.00-$45.51M
2023-12-31-$25.46M$541,000.00-$26M
2023-03-31-$34.24M$1.06M-$35.3M
2022-12-31-$21.44M$351,000.00-$21.79M
2022-03-31-$1.43M$147,000.00-$1.57M
2021-12-31-$19.57M$159,000.00-$19.72M
2021-03-31-$10.51M$210,000.00-$10.72M
2020-12-31-$7.99M$60,000.00-$8.05M
2020-03-31-$8.12M$176,000.00-$8.3M
2019-12-31-$5.5M$18,000.00-$5.52M
2019-03-31-$2.51M$0.00-$2.51M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31$107.51M$1.55M$105.95M121.77%
2024-12-31-$160.87M$1.93M-$162.8M
2023-12-31-$124.51M$2.46M-$126.97M
2022-12-31-$70.06M$1.24M-$71.3M
2021-12-31-$62.15M$1.02M-$63.17M
2020-12-31-$36.89M$294,000.00-$37.19M
2019-12-31-$16M$271,000.00-$16.27M